European ADHD Study Delivers Positive Results
| Stock | Blinklab Ltd (BB1.ASX) |
|---|---|
| Release Time | 5 Aug 2026, 9:15 a.m. |
| Price Sensitive | Yes |
Blinklab Ltd: Positive Results from European ADHD Study
- Strong study results: 82% sensitivity and 83% specificity in children aged 6-17
- Supports development of BlinkLab Dx2 for ADHD detection
- Capital-efficient study completed in collaboration with Mental Care Group
Blinklab Ltd announced positive results from its European ADHD study, achieving 82% sensitivity and 83% specificity in children aged 6-17 years. The study, conducted in collaboration with Mental Care Group, utilized smartphone-based assessments to collect digital neurobehavioural biomarkers. The findings support the development of BlinkLab Dx2, the company's novel AI model designed to detect ADHD in addition to autism. The study cohort represents one of the largest case-control datasets reported for ADHD assessment tools. BlinkLab plans to initiate a U.S. pilot study in collaboration with leading ADHD clinical centres, followed by a prospective FDA registrational study.
Blinklab Ltd achieved 82% sensitivity and 83% specificity in the European ADHD study.
BlinkLab plans to initiate a U.S. pilot study followed by a prospective FDA registrational study.